These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 23879705)

  • 21. Peginterferon alfa-2a and peginterferon alfa-2b combined with ribavirin in patients with genotype 1 chronic hepatitis C: results of a prospective single-centre study.
    Berak H; Laskus T; Kołakowska-Rządzka A; Wasilewski M; Stańczak JJ; Bardadin K; Walewska-Zielecka B; Horban A
    Adv Med Sci; 2014 Sep; 59(2):261-5. PubMed ID: 25117425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peginterferon and dose-titrated ribavirin for hepatitis C-associated nephrotic membranoproliferative glomerulonephritis type 1.
    Orlent H; Mathot RA; Van Bommel EF; Vulto AG; Schalm SW; Brouwer JT
    Dig Dis Sci; 2005 Oct; 50(10):1804-6. PubMed ID: 16187177
    [No Abstract]   [Full Text] [Related]  

  • 23. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
    Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiviral therapy for hepatitis C virus infection, cryoglobulinemic glomerulonephritis and low-grade malignant lymphoma: A challenge?
    Ennaifer R; Sabbah M; Hefaiedh R; Romdhane H; Cheikh M; Belhadj N
    Tunis Med; 2015 Mar; 93(3):203-4. PubMed ID: 26367421
    [No Abstract]   [Full Text] [Related]  

  • 25. Factors associated with efficacy of pegylated interferon-α plus ribavirin for chronic hepatitis C after renal transplantation.
    Li LF; Shi KQ; Lin YQ; Wang LR; He JP; Braddock M; Chen YP; Zheng MH
    Gene; 2014 Jul; 544(2):101-6. PubMed ID: 24793583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
    Hézode C; Forestier N; Dusheiko G; Ferenci P; Pol S; Goeser T; Bronowicki JP; Bourlière M; Gharakhanian S; Bengtsson L; McNair L; George S; Kieffer T; Kwong A; Kauffman RS; Alam J; Pawlotsky JM; Zeuzem S;
    N Engl J Med; 2009 Apr; 360(18):1839-50. PubMed ID: 19403903
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients].
    He LL; Chen Z; Chen Y; Xu H; Tang H; Lei BJ; Lei XZ
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):34-7. PubMed ID: 21272456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
    Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Steroids, interferon-alpha and ribavirin treatment of cryoglobulinemic glomerulonephritis concurrent with HCV infection].
    Guarnieri A; Marazzi F; Giorgi MP; Canepari G; Pino C; Moggia E; Manca A; Ghezzi PM
    G Ital Nefrol; 2002; 19(1):79-81. PubMed ID: 12165950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of chronic hepatitis C in human immunodeficiency virus/hepatitis C virus-coinfected patients in the era of pegylated interferon and ribavirin.
    Bräu N
    Semin Liver Dis; 2005 Feb; 25(1):33-51. PubMed ID: 15731996
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial.
    Pessôa MG; Cheinquer H; Almeida PR; Silva GF; Lima MP; Paraná R; Lacerda MA; Parise ER; Pernambuco JR; Pedrosa SS; Teixeira R; Sette H; Tatsch F
    Ann Hepatol; 2012; 11(1):52-61. PubMed ID: 22166561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection.
    von Wagner M; Hofmann WP; Teuber G; Berg T; Goeser T; Spengler U; Hinrichsen H; Weidenbach H; Gerken G; Manns M; Buggisch P; Herrmann E; Zeuzem S
    Hepatology; 2008 Nov; 48(5):1404-11. PubMed ID: 18846541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HCV-related cryoglobulinemic glomerulonephritis: implications of antiviral and immunosuppressive therapies.
    Garini G; Allegri L; Lannuzzella F; Vaglio A; Buzio C
    Acta Biomed; 2007; 78(1):51-9. PubMed ID: 17687818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of pegylated interferon-alpha-2a plus ribavirin for patients aged at least 60 years with chronic hepatitis C.
    Zheng YY; Fan XH; Wang LF; Tian D; Huo N; Lu HY; Wu CH; Xu XY; Wei L
    Chin Med J (Engl); 2012 Jun; 125(11):1852-6. PubMed ID: 22884041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Virological response of Tunisians patients treated by peginterferon plus ribavirin for chronic hepatitis C: a preliminary study.
    Belhadj N; Houissa F; Elloumi H; Ouakaa A; Gargouri D; Romani M; Kilani A; Kochlef A; Kharrat J; Ghorbel A
    Tunis Med; 2008 Apr; 86(4):341-5. PubMed ID: 19476135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.
    Hu CC; Lin CL; Kuo YL; Chien CH; Chen SW; Yen CL; Lin CY; Chien RN
    Aliment Pharmacol Ther; 2013 Jan; 37(1):81-90. PubMed ID: 23121150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Peginterferon α-2a and rivabirin in the treatment of chronic hepatitis C.
    Rahman MZ; Perveen S; Mahmuduzzaman M; Rahman MA; Chowdhury MS; Huda MN; Ahmed DS; Raihan MA
    Mymensingh Med J; 2014 Apr; 23(2):335-40. PubMed ID: 24858163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C].
    Kim CH; Park BD; Lee JW; Kim YS; Jeong S; Lee DH; Kim HG; Shin YW; Kwon KS; Lee JI
    Korean J Hepatol; 2009 Mar; 15(1):70-9. PubMed ID: 19346787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.